WO2021068925A1 - 改进的尿酸酶及其用于治疗高尿酸血症的方法 - Google Patents
改进的尿酸酶及其用于治疗高尿酸血症的方法 Download PDFInfo
- Publication number
- WO2021068925A1 WO2021068925A1 PCT/CN2020/120133 CN2020120133W WO2021068925A1 WO 2021068925 A1 WO2021068925 A1 WO 2021068925A1 CN 2020120133 W CN2020120133 W CN 2020120133W WO 2021068925 A1 WO2021068925 A1 WO 2021068925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- uricase
- variant
- sequence
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
分子名称 | 位点突变 | 单亚基个数 | 酶活保持 | 修饰后酶活U/mg |
AG-2C12 | S142C/E216C | 2 | 98% | 2.0 |
AG-2C13 | A35C/S288C | 2 | 90% | 1.95 |
AG-2C16 | A35C/S142C | 2 | 98% | 1.69 |
AG-2C17 | E216C/S288C | 2 | 90% | 1.85 |
AG-2C13-1 | A35C/S288C | 2 | 113% | 2.33 |
AG-2C01-2 | A35C/T194C | 2 | 99% | 1.55 |
AG-2C05-1 | F82C/G287C | 2 | 44% | 0.67 |
AG-2C01-1 | A35C/T194C | 2 | 92% | 1.43 |
AG-2C12-1 | S142C/E216C | 2 | 102% | 1.65 |
分子名称 | Km | Vmax | Kcat |
AG-2C01-2-PEG | 451.4 | 13.84 | 5.4 |
AG-2C12-PEG | 355.5 | 13.24 | 5.3 |
AG-2C13-PEG | 167.7 | 9.4 | 3.6 |
MEDI4945 | 101.5 | 6.8 | 2.6 |
Claims (15)
- 一种尿酸酶,包含与SEQ ID NO:1具有至少约90%、91%、92%、93%、94%、95%、96%、97%、98%或99%的一致性的氨基酸序列,且所述序列不是SEQ ID NO:1。
- 如权利要求1所述的尿酸酶,其特征在于,与SEQ ID NO:1的序列相比,所述尿酸酶的氨基酸序列中包含1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21或22个氨基酸残基的添加、缺失或取代。
- 如权利要求2所述的尿酸酶,其特征在于,所述尿酸酶为在N-末端和/或C-末端处被截短的SEQ ID NO:1的片段,其中该片段保留了酶活性;优选地,所述截短为N末端17个以内的氨基酸残基的截短,和/或C末端5个以内的氨基酸残基的截短;任选地,N末端截短后,添加了8个以内的氨基酸残基。
- 如权利要求3所述的尿酸酶,其特征在于,所述截短为N末端截短了17个氨基酸,即MTATAETSTGTKVVLGQ;所述添加为添加了MTNIILGK或MANIILGK的氨基酸序列;和/或所述截短为C末端截短了5个氨基酸,即IAGFC。
- 如权利要求1所述的尿酸酶,其特征在于,与SEQ ID NO:1相比,所述尿酸酶的氨基酸序列在对应于SEQ ID NO:1第175、178和258位置的至少一个位置上具有取代突变;优选地,第175位上取代后的氨基酸残基为脯氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、苯丙氨酸、色氨酸或蛋氨酸;优选地,第178位上取代后的氨基酸残基是谷氨酸或天冬氨酸;优选地,第258位上取代后的氨基酸残基是丝氨酸、谷氨酸、苏氨酸、酪氨酸、天冬酰胺或谷氨酰胺。
- 如权利要求1-5中任一项所述的尿酸酶,其特征在于,所述尿酸酶序列中经突变引入1-6个表面可及的半胱氨酸残基,并任选的在第205和/或第208位存在取代突变,其中位置编号是相对于SEQ ID NO:1或3。
- 如权利要求6所述的尿酸酶,其特征在于,所述尿酸酶在以下位置中的1-6个包含半胱氨酸残基:35、82、142、194、216、287和288,其中位置编号是相对于SEQ ID NO:1或3;优选地,所述尿酸酶在以下位置中的两个包含半胱氨酸残基:35、82、142、194、216、287和288,其中位置编号是相对于SEQ ID NO:1或3;更优选地,所述尿酸酶在以下两个位置中包含半胱氨酸残基:142和216,35和288, 35和142,216和288,35和194,或82和287,其中位置编号是相对于SEQ ID NO:1或3。
- 如权利要求1所述的尿酸酶,其特征在于,所述尿酸酶的氨基酸序列如SEQ ID NO:3、4、5、6、7或8所示;或其氨基酸序列为在SEQ ID NO:3的序列的以下两个位置中包含半胱氨酸的氨基酸序列:142和216,35和288,35和142,216和288,35和194,或82和287,并任选地在SEQ ID NO:3第205位和/或第208位存在取代突变,优选地,所述取代突变为SEQ ID NO:3第205位的S被取代成D或E、第208位的G被取代成R、K或S。
- 如权利要求8所述的尿酸酶,其特征在于,所述尿酸酶的氨基酸序列为在SEQ ID NO:3的序列的以下两个位置中包含半胱氨酸的氨基酸序列:142和216,35和288,35和142,216和288,35和194,或82和287,并任选地包含S205D和/或G208R的取代突变。
- 如权利要求9所述的尿酸酶,其特征在于,所述尿酸酶的氨基酸序列:为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第142位和第216位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第288位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第142位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第216位和第288位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第194位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第82位和第287位的氨基酸残基均为C;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第142位和第216位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第288位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第142位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第216位和第288 位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第35位和第194位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R;或为SEQ ID NO:3的变体,其中,与SEQ ID NO:3相比,所述变体第82位和第287位的氨基酸残基均为C,第205位氨基酸残基为D,第208位氨基酸残基为R。
- 一种偶联物,其含有权利要求1-10中任一项所述的尿酸酶和与该尿酸酶共价连接或融合表达的合成的聚合物。
- 如权利要求11所述的偶联物,其特征在于,所述聚合物选自聚乙二醇(PEG)、磷酰胆碱聚合物、重复肽或“X-TEN”序列的聚合物和基于碳水化合物的聚合物。
- 如权利要求12所述的偶联物,其特征在于,所述聚合物与所述尿酸酶的N-末端和/或C-末端融合表达,或通过所述尿酸酶上存在的半胱氨酸残基进行共价连接。
- 一种药物组合物,其含有权利要求1-10中任一项所述的尿酸酶或权利要求11-13中任一项所述的偶联物,和药学上可接受的载体。
- 权利要求1-10中任一项所述的尿酸酶、权利要求11-13中任一项所述的偶联物或权利要求14所述的药物组合物在制备降低哺乳动物体液和组织中尿酸水平或治疗高尿酸血症的药物中的用途。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022521317A JP2022553648A (ja) | 2019-10-11 | 2020-10-10 | 改良されたウリカーゼ及びそれを使用した高尿酸血症の治療方法 |
KR1020227015028A KR20220078647A (ko) | 2019-10-11 | 2020-10-10 | 개선된 유리카제 및 그의 고요산혈증을 치료하기 위한 방법 |
US17/767,718 US20230073183A1 (en) | 2019-10-11 | 2020-10-10 | Improved uricase and method for treating hyperuricemia using same |
AU2020362820A AU2020362820A1 (en) | 2019-10-11 | 2020-10-10 | Improved uricase and method for treating hyperuricemia using same |
BR112022005757A BR112022005757A2 (pt) | 2019-10-11 | 2020-10-10 | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma |
EP20874785.7A EP4043559A1 (en) | 2019-10-11 | 2020-10-10 | Improved uricase and method for treating hyperuricemia using same |
CA3153029A CA3153029A1 (en) | 2019-10-11 | 2020-10-10 | Improved uricase and method for treating hyperuricemia using same |
CN202080070950.5A CN114502728A (zh) | 2019-10-11 | 2020-10-10 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910964325.4 | 2019-10-11 | ||
CN201910964325.4A CN112646790A (zh) | 2019-10-11 | 2019-10-11 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021068925A1 true WO2021068925A1 (zh) | 2021-04-15 |
Family
ID=75342725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/120133 WO2021068925A1 (zh) | 2019-10-11 | 2020-10-10 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230073183A1 (zh) |
EP (1) | EP4043559A1 (zh) |
JP (1) | JP2022553648A (zh) |
KR (1) | KR20220078647A (zh) |
CN (2) | CN112646790A (zh) |
AU (1) | AU2020362820A1 (zh) |
BR (1) | BR112022005757A2 (zh) |
CA (1) | CA3153029A1 (zh) |
WO (1) | WO2021068925A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022214086A1 (zh) * | 2021-04-09 | 2022-10-13 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
WO2023064732A1 (en) * | 2021-10-15 | 2023-04-20 | Georgia State University Research Foundation, Inc. | Delivery of therapeutic recombinant uricase using nanoparticles |
CN117230034A (zh) * | 2023-10-16 | 2023-12-15 | 临沂大学 | 一种高稳定性哺乳动物尿酸氧化酶突变体 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322243A (zh) * | 1998-08-06 | 2001-11-14 | 杜克大学 | 尿酸氧化酶 |
CN101198693A (zh) * | 2005-04-11 | 2008-06-11 | 萨文特医药公司 | 尿酸氧化酶的变体形式及其用途 |
CN101875922A (zh) * | 2009-04-30 | 2010-11-03 | 重庆医科大学 | 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用 |
CN105543187A (zh) * | 2016-02-18 | 2016-05-04 | 重庆医科大学 | 苛求芽孢杆菌尿酸酶突变体v145a |
CN106554948A (zh) * | 2015-09-29 | 2017-04-05 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
CN107614007A (zh) * | 2015-05-15 | 2018-01-19 | 免疫医疗有限责任公司 | 改进的尿酸酶序列和治疗方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188971A1 (en) * | 1998-08-06 | 2006-08-24 | Duke University | Urate oxidase |
KR101637010B1 (ko) * | 2015-04-24 | 2016-07-07 | 광주과학기술원 | 위치 특이적으로 알부민이 연결된 요산 산화효소 및 단백질에 위치 특이적으로 알부민을 연결하는 방법 |
US20200308534A1 (en) * | 2017-07-07 | 2020-10-01 | Allena Pharmaceuticals, Inc. | Recombinant uricase enzyme |
CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
CN115197923A (zh) * | 2021-04-09 | 2022-10-18 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
-
2019
- 2019-10-11 CN CN201910964325.4A patent/CN112646790A/zh active Pending
-
2020
- 2020-10-10 EP EP20874785.7A patent/EP4043559A1/en active Pending
- 2020-10-10 JP JP2022521317A patent/JP2022553648A/ja active Pending
- 2020-10-10 CN CN202080070950.5A patent/CN114502728A/zh active Pending
- 2020-10-10 AU AU2020362820A patent/AU2020362820A1/en active Pending
- 2020-10-10 CA CA3153029A patent/CA3153029A1/en active Pending
- 2020-10-10 KR KR1020227015028A patent/KR20220078647A/ko active Search and Examination
- 2020-10-10 US US17/767,718 patent/US20230073183A1/en active Pending
- 2020-10-10 WO PCT/CN2020/120133 patent/WO2021068925A1/zh unknown
- 2020-10-10 BR BR112022005757A patent/BR112022005757A2/pt unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322243A (zh) * | 1998-08-06 | 2001-11-14 | 杜克大学 | 尿酸氧化酶 |
CN101198693A (zh) * | 2005-04-11 | 2008-06-11 | 萨文特医药公司 | 尿酸氧化酶的变体形式及其用途 |
CN101875922A (zh) * | 2009-04-30 | 2010-11-03 | 重庆医科大学 | 来自苛求芽孢杆菌的两种尿酸酶和其突变体及它们的聚乙二醇修饰与应用 |
CN107614007A (zh) * | 2015-05-15 | 2018-01-19 | 免疫医疗有限责任公司 | 改进的尿酸酶序列和治疗方法 |
CN106554948A (zh) * | 2015-09-29 | 2017-04-05 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
CN105543187A (zh) * | 2016-02-18 | 2016-05-04 | 重庆医科大学 | 苛求芽孢杆菌尿酸酶突变体v145a |
Non-Patent Citations (11)
Title |
---|
"NCBI", Database accession no. D0VWQ1.1 |
"PCR TECHNOLOGY", 1989, STOCKTON PRESS |
"Pharmaceutical Dosage Forms: Disperse Systems", 1990, MARCEL DEKKER |
"Pharmaceutical Dosage Forms: Parenteral Medications", 1993, MARCEL DEKKER |
"U.S. Pharmacopeia: National Formulary", 1984, MACK PUBLISHING COMPANY |
DATABASE UNIPROTKB 5 April 2011 (2011-04-05), ANONYMOUS: "UniProtKB/Swiss-Prot:D0VWQ1.1", XP055799981, retrieved from UNIPROT Database accession no. D0VWQ1 * |
HARDMAN ET AL.: "Goodman and Gilman's: The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL |
MAYNARD ET AL.: "A Handbook of SOPs for Good Clinical Practice", 1996, INTERPHARM PRESS |
MULLIS ET AL., COLD SPRING HARBOR SYMP QUANT. BIOL., vol. 51, 1987, pages 263 |
TAO LEI, LI DANDAN, LI YONGHONG, SHI XINCHANG, WANG JUNZHI, RAO CHUNMING, ZHANG YINGQI: "Designing a mutant Candida uricase with improved polymerization state and enzymatic activity", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 30, no. 11, 1 November 2017 (2017-11-01), GB, pages 753 - 759, XP055799984, ISSN: 1741-0126, DOI: 10.1093/protein/gzx056 * |
WEINERKOTKOSKIE: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS, AND WILKINS |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022214086A1 (zh) * | 2021-04-09 | 2022-10-13 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
CN115197923A (zh) * | 2021-04-09 | 2022-10-18 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2022553648A (ja) | 2022-12-26 |
CA3153029A1 (en) | 2021-04-15 |
EP4043559A1 (en) | 2022-08-17 |
CN114502728A (zh) | 2022-05-13 |
CN112646790A (zh) | 2021-04-13 |
BR112022005757A2 (pt) | 2022-06-21 |
AU2020362820A1 (en) | 2022-05-05 |
US20230073183A1 (en) | 2023-03-09 |
KR20220078647A (ko) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021068925A1 (zh) | 改进的尿酸酶及其用于治疗高尿酸血症的方法 | |
AU2017245352B2 (en) | Ph20 polypeptide variants, formulations and uses thereof | |
KR101647933B1 (ko) | 활성화가능한 기질-분해효소의 생체내 시간적 조절 | |
ES2255147T3 (es) | Arginina deiminasa derivada de mycoplasma arthritidis y conjugados de polimeros que la contienen. | |
EP2799540B1 (en) | Human arginase and pegylated human arginase and application thereof | |
US20150010529A1 (en) | Thermally stable ph20 hyaluronidase variants and uses thereof | |
JP2020528742A (ja) | 改変された膜型セリンプロテアーゼ1(mtsp−1)ポリペプチドおよび使用方法 | |
US8859251B2 (en) | Oligoadenylate synthetase (OAS) | |
WO2007058381A1 (ja) | 基質特異性を変換した新規高機能酵素 | |
KR20130084323A (ko) | Oas1 유전자에서의 돌연변이 | |
AU752370B2 (en) | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence | |
KR20190026813A (ko) | 시스틴의 인간-효소 매개된 고갈 | |
WO2022214086A1 (zh) | 尿酸酶、其药物组合物及其用途 | |
US10406214B2 (en) | Propionyl-CoA carboxylase compositions and uses thereof | |
US9322008B2 (en) | Mutants of L-asparaginase | |
JP5678664B2 (ja) | ヒトβ−ヘキソサミニダーゼBの基質特異性を変換した新規高機能酵素 | |
US20210309984A1 (en) | ChiA Enzyme | |
WO2024046280A1 (zh) | 一种聚乙二醇修饰的il-21衍生物及其应用 | |
TW201828926A (zh) | 聚乙二醇化精胺酸脫亞胺酶之調配物 | |
WO2021209930A1 (en) | Setd7 epigenetic modulators | |
EP4323532A1 (en) | Delivery of gene therapy vectors | |
NZ720075B2 (en) | Ph20 polypeptide variants, formulations and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20874785 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3153029 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022005757 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022521317 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227015028 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020362820 Country of ref document: AU Date of ref document: 20201010 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020874785 Country of ref document: EP Effective date: 20220511 |
|
ENP | Entry into the national phase |
Ref document number: 112022005757 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220325 |